Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye.

According to the law firm press release, the lawsuit alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Ocular Therapeutix’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could imperil the approval of DEXTENZA by the FDA; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On October 27, 2017, this case was transferred to the United States District Court for the District of Massachusetts. The transferred case was opened as 17-CV-12146. On March 9, 2018, the Court issued an Order consolidating cases and approving Lead Plaintiffs and Counsel. The cases shall be consolidated under Docket 17-CV-12288 and identified as "In re Ocular Therapeutix, Inc. Securities Litigation."

Lead Plaintiffs filed a consolidated amended Complaint on May 7, 2018. Defendants filed a Motion to Dismiss the consolidated amended Complaint on July 6. On April 30, 2019, the Court issued an Order granting Defendants' Motion to Dismiss. Lead Plaintiffs filed a Notice appealing the Court's Dismissal Order on May 31. On April 9, 2020, the Court of Appeals affirmed the District Court's judgment.